Amgen’s dazodalibep Phase 3 trial clears Sjögren’s hurdle
Amgen's dazodalibep Phase 3 trial met its primary endpoint in systemic Sjögren's disease, sending AMGN shares higher on 22 September 2026.
Topic
biopharma
Every Financial News story tagged biopharma, newest first.
- Stories
- 3
- Last updated
- Follow
- RSS feed
All stories
1–3 of 3
Revolutionising Biological Systems with AI Basecamp Research’s New Funding and Vision
Basecamp Research has recently secured $60 million to advance its groundbreaking AI-driven exploration of biological systems. This funding marks a pivotal moment in integrating biodiversity with technological innovation.With significant backing…
Rivia Secures €3M to Enhance AI in Clinical Trials
Swiss startup Rivia has emerged as a frontrunner in AI-driven clinical trial analytics, securing €3 million in funding. This development positions the company to lead innovation in biopharma analytics.The investment,…
